Table 1 Clinical and pathological features of patient group
From: Systemic therapy response evaluation in prostate carcinoma with [68Ga]Ga-PSMA-11 PET/CT
Feature | Â | Total | |
|---|---|---|---|
Gleason score | 7 | 7 (26.9%) | 26 (100%) |
8 | 9 (34.6%) | ||
9 | 8 (30.8%) | ||
10 | 2 (7.7%) | ||
ISUP score | 1 | 0 | 26 (100%) |
2 | 2 (7.7%) | ||
3 | 5 (19.2%) | ||
4 | 9 (34.6%) | ||
5 | 10 (38.5%) | ||
Risk classification | High risk | 29 (90.6%) | 31 (100%) |
Intermediate risk | 2 (9.4%) | ||
Low risk | 0 | ||
Definitive therapy to prostate gland | None | 41 (87.2%) | 47 (100%) |
Total prostatectomy | 3 (6.4%) | ||
Radiotherapy | 3 (6.4%) | ||
Serum PSA value at diagnosis | Mean ± standart deviation (minimum–maximum) | 510.72 ± 1127.49 (0.22–5476) |  |